Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 805 to 811 of 811 entries
Sorted by: Best Match Show Resources per page
Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer.

Frontiers in neurology

Lukas C, Bellenberg B, Prados F, Valsasina P, Parmar K, Brouwer I, Pareto D, Rovira À, Sastre-Garriga J, Gandini Wheeler-Kingshott CAM, Kappos L, Rocca MA, Filippi M, Yiannakas M, Barkhof F, Vrenken H.
PMID: 34421797
Front Neurol. 2021 Aug 04;12:693333. doi: 10.3389/fneur.2021.693333. eCollection 2021.

No abstract available.

Cite
Lukas C, Bellenberg B, Prados F, et al. Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Front Neurol. 2021;12:693333doi: 10.3389/fneur.2021.693333.
Lukas, C., Bellenberg, B., Prados, F., Valsasina, P., Parmar, K., Brouwer, I., Pareto, D., Rovira, �. �., Sastre-Garriga, J., Gandini Wheeler-Kingshott, C. A. M., Kappos, L., Rocca, M. A., Filippi, M., Yiannakas, M., Barkhof, F., & Vrenken, H. (2021). Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Frontiers in neurology, 12693333. https://doi.org/10.3389/fneur.2021.693333
Lukas, Carsten, et al. "Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer." Frontiers in neurology vol. 12 (2021): 693333. doi: https://doi.org/10.3389/fneur.2021.693333
Lukas C, Bellenberg B, Prados F, Valsasina P, Parmar K, Brouwer I, Pareto D, Rovira À, Sastre-Garriga J, Gandini Wheeler-Kingshott CAM, Kappos L, Rocca MA, Filippi M, Yiannakas M, Barkhof F, Vrenken H. Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. Front Neurol. 2021 Aug 04;12:693333. doi: 10.3389/fneur.2021.693333. eCollection 2021. PMID: 34421797; PMCID: PMC8371197.
Copy Download .nbib Format: NLM
Electrospun PCL-Based Vascular Grafts: In Vitro Tests.

Nanomaterials (Basel, Switzerland)

Zavan B, Gardin C, Guarino V, Rocca T, Cruz Maya I, Zanotti F, Ferroni L, Brunello G, Chachques JC, Ambrosio L, Gasbarro V.
PMID: 33809791
Nanomaterials (Basel). 2021 Mar 16;11(3). doi: 10.3390/nano11030751.

BACKGROUND: Electrospun fibers have attracted a lot of attention from researchers due to their several characteristics, such as a very thin diameter, three-dimensional topography, large surface area, flexible surface, good mechanical characteristics, suitable for widespread applications. Indeed, electro-spinning offers...

Cite
Zavan B, Gardin C, Guarino V, et al. Electrospun PCL-Based Vascular Grafts: In Vitro Tests. Nanomaterials (Basel). 2021;11(3)doi: 10.3390/nano11030751.
Zavan, B., Gardin, C., Guarino, V., Rocca, T., Cruz Maya, I., Zanotti, F., Ferroni, L., Brunello, G., Chachques, J. C., Ambrosio, L., & Gasbarro, V. (2021). Electrospun PCL-Based Vascular Grafts: In Vitro Tests. Nanomaterials (Basel, Switzerland), 11(3), . https://doi.org/10.3390/nano11030751
Zavan, Barbara, et al. "Electrospun PCL-Based Vascular Grafts: In Vitro Tests." Nanomaterials (Basel, Switzerland) vol. 11,3 (2021). doi: https://doi.org/10.3390/nano11030751
Zavan B, Gardin C, Guarino V, Rocca T, Cruz Maya I, Zanotti F, Ferroni L, Brunello G, Chachques JC, Ambrosio L, Gasbarro V. Electrospun PCL-Based Vascular Grafts: In Vitro Tests. Nanomaterials (Basel). 2021 Mar 16;11(3). doi: 10.3390/nano11030751. PMID: 33809791; PMCID: PMC8002398.
Copy Download .nbib Format: NLM
Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses.

JAMA psychiatry

Mucci A, Galderisi S, Gibertoni D, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M, Bellomo A, Biondi M, Blasi G, Brasso C, Bucci P, Carpiniello B, Cuomo A, Dell'Osso L, Giordano GM, Marchesi C, Monteleone P, Niolu C, Oldani L, Pettorruso M, Pompili M, Roncone R, Rossi R, Tenconi E, Vita A, Zeppegno P, Maj M.
PMID: 33566071
JAMA Psychiatry. 2021 May 01;78(5):550-559. doi: 10.1001/jamapsychiatry.2020.4614.

IMPORTANCE: The goal of schizophrenia treatment has shifted from symptom reduction and relapse prevention to functional recovery; however, recovery rates remain low. Prospective identification of variables associated with real-life functioning domains is essential for personalized and integrated treatment programs.OBJECTIVE:...

Cite
Mucci A, Galderisi S, Gibertoni D, et al. Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry. 2021;78(5):550-559doi: 10.1001/jamapsychiatry.2020.4614.
Mucci, A., Galderisi, S., Gibertoni, D., Rossi, A., Rocca, P., Bertolino, A., Aguglia, E., Amore, M., Bellomo, A., Biondi, M., Blasi, G., Brasso, C., Bucci, P., Carpiniello, B., Cuomo, A., Dell'Osso, L., Giordano, G. M., Marchesi, C., Monteleone, P., Niolu, C., Oldani, L., Pettorruso, M., Pompili, M., Roncone, R., Rossi, R., Tenconi, E., Vita, A., Zeppegno, P., Maj, M. (2021). Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA psychiatry, 78(5), 550-559. https://doi.org/10.1001/jamapsychiatry.2020.4614
Mucci, Armida, et al. "Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses." JAMA psychiatry vol. 78,5 (2021): 550-559. doi: https://doi.org/10.1001/jamapsychiatry.2020.4614
Mucci A, Galderisi S, Gibertoni D, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M, Bellomo A, Biondi M, Blasi G, Brasso C, Bucci P, Carpiniello B, Cuomo A, Dell'Osso L, Giordano GM, Marchesi C, Monteleone P, Niolu C, Oldani L, Pettorruso M, Pompili M, Roncone R, Rossi R, Tenconi E, Vita A, Zeppegno P, Maj M. Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry. 2021 May 01;78(5):550-559. doi: 10.1001/jamapsychiatry.2020.4614. PMID: 33566071; PMCID: PMC7876615.
Copy Download .nbib Format: NLM
Economic evaluation of CPAP therapy for obstructive sleep apnea: a scoping review and evidence map.

Sleep & breathing = Schlaf & Atmung

Pachito DV, Bagattini ÂM, Drager LF, Eckeli AL, Rocha A.
PMID: 33788132
Sleep Breath. 2021 Mar 31; doi: 10.1007/s11325-021-02362-8. Epub 2021 Mar 31.

PURPOSE: To synthesize findings of economic evaluations investigating cost-effectiveness of continuous positive airway pressure (CPAP) for obstructive sleep apnea (OSA) and of strategies of organization of care related to CPAP therapy.METHODS: Scoping review with searches conducted in MEDLINE, CRD,...

Cite
Pachito DV, Bagattini ÂM, Drager LF, et al. Economic evaluation of CPAP therapy for obstructive sleep apnea: a scoping review and evidence map. Sleep Breath. 2021;doi: 10.1007/s11325-021-02362-8.
Pachito, D. V., Bagattini, �. �. M., Drager, L. F., Eckeli, A. L., & Rocha, A. (2021). Economic evaluation of CPAP therapy for obstructive sleep apnea: a scoping review and evidence map. Sleep & breathing = Schlaf & Atmung, . https://doi.org/10.1007/s11325-021-02362-8
Pachito, Daniela V, et al. "Economic evaluation of CPAP therapy for obstructive sleep apnea: a scoping review and evidence map." Sleep & breathing = Schlaf & Atmung vol. (2021). doi: https://doi.org/10.1007/s11325-021-02362-8
Pachito DV, Bagattini ÂM, Drager LF, Eckeli AL, Rocha A. Economic evaluation of CPAP therapy for obstructive sleep apnea: a scoping review and evidence map. Sleep Breath. 2021 Mar 31; doi: 10.1007/s11325-021-02362-8. Epub 2021 Mar 31. PMID: 33788132.
Copy Download .nbib Format: NLM
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)

Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M.
PMID: 34378456
Mult Scler. 2021 Aug 11;13524585211032803. doi: 10.1177/13524585211032803. Epub 2021 Aug 11.

BACKGROUND: Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS).OBJECTIVE: Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).METHODS: CONCERTO was a randomized, double-blind, placebo-controlled, phase-3 study. RRMS patients were randomized 1:1:1...

Cite
Comi G, Dadon Y, Sasson N, et al. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler. 2021;13524585211032803doi: 10.1177/13524585211032803.
Comi, G., Dadon, Y., Sasson, N., Steinerman, J. R., Knappertz, V., Vollmer, T. L., Boyko, A., Vermersch, P., Ziemssen, T., Montalban, X., Lublin, F. D., Rocca, M. A., Volkinshtein, R., Rubinchick, S., Halevy, N., & Filippi, M. (2021). CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 13524585211032803. https://doi.org/10.1177/13524585211032803
Comi, Giancarlo, et al. "CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis." Multiple sclerosis (Houndmills, Basingstoke, England) vol. (2021): 13524585211032803. doi: https://doi.org/10.1177/13524585211032803
Comi G, Dadon Y, Sasson N, Steinerman JR, Knappertz V, Vollmer TL, Boyko A, Vermersch P, Ziemssen T, Montalban X, Lublin FD, Rocca MA, Volkinshtein R, Rubinchick S, Halevy N, Filippi M. CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. Mult Scler. 2021 Aug 11;13524585211032803. doi: 10.1177/13524585211032803. Epub 2021 Aug 11. PMID: 34378456.
Copy Download .nbib Format: NLM
Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold.

Digestive diseases (Basel, Switzerland)

Compare D, Sgamato C, Nardone OM, Rocco A, Coccoli P, Laurenza C, Nardone G.
PMID: 33752212
Dig Dis. 2021 Mar 22; doi: 10.1159/000516023. Epub 2021 Mar 22.

BACKGROUND: Multiple lines of evidence now support the notion that gut microbiota can contribute to digestive and extra-digestive diseases. The emergence of these observations enabled to postulate a bacteria-centric paradigm to rethink the treatment of many diseases. The goal...

Cite
Compare D, Sgamato C, Nardone OM, et al. Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold. Dig Dis. 2021;doi: 10.1159/000516023.
Compare, D., Sgamato, C., Nardone, O. M., Rocco, A., Coccoli, P., Laurenza, C., & Nardone, G. (2021). Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold. Digestive diseases (Basel, Switzerland), . https://doi.org/10.1159/000516023
Compare, Debora, et al. "Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold." Digestive diseases (Basel, Switzerland) vol. (2021). doi: https://doi.org/10.1159/000516023
Compare D, Sgamato C, Nardone OM, Rocco A, Coccoli P, Laurenza C, Nardone G. Probiotics in Gastrointestinal Diseases: All that Glitters Is Not Gold. Dig Dis. 2021 Mar 22; doi: 10.1159/000516023. Epub 2021 Mar 22. PMID: 33752212.
Copy Download .nbib Format: NLM
Alterations of the gut mycobiome in patients with MS.

EBioMedicine

Shah S, Locca A, Dorsett Y, Cantoni C, Ghezzi L, Lin Q, Bokoliya S, Panier H, Suther C, Gormley M, Liu Y, Evans E, Mikesell R, Obert K, Salter A, Cross AH, Tarr PI, Lovett-Racke A, Piccio L, Zhou Y.
PMID: 34455391
EBioMedicine. 2021 Sep;71:103557. doi: 10.1016/j.ebiom.2021.103557. Epub 2021 Aug 26.

BACKGROUND: The mycobiome is the fungal component of the gut microbiome and is implicated in several autoimmune diseases. However, its role in MS has not been studied.METHODS: In this case-control observational study, we performed ITS sequencing and characterised the...

Cite
Shah S, Locca A, Dorsett Y, et al. Alterations of the gut mycobiome in patients with MS. EBioMedicine. 2021;71:103557doi: 10.1016/j.ebiom.2021.103557.
Shah, S., Locca, A., Dorsett, Y., Cantoni, C., Ghezzi, L., Lin, Q., Bokoliya, S., Panier, H., Suther, C., Gormley, M., Liu, Y., Evans, E., Mikesell, R., Obert, K., Salter, A., Cross, A. H., Tarr, P. I., Lovett-Racke, A., Piccio, L., & Zhou, Y. (2021). Alterations of the gut mycobiome in patients with MS. EBioMedicine, 71103557. https://doi.org/10.1016/j.ebiom.2021.103557
Shah, Saumya, et al. "Alterations of the gut mycobiome in patients with MS." EBioMedicine vol. 71 (2021): 103557. doi: https://doi.org/10.1016/j.ebiom.2021.103557
Shah S, Locca A, Dorsett Y, Cantoni C, Ghezzi L, Lin Q, Bokoliya S, Panier H, Suther C, Gormley M, Liu Y, Evans E, Mikesell R, Obert K, Salter A, Cross AH, Tarr PI, Lovett-Racke A, Piccio L, Zhou Y. Alterations of the gut mycobiome in patients with MS. EBioMedicine. 2021 Sep;71:103557. doi: 10.1016/j.ebiom.2021.103557. Epub 2021 Aug 26. PMID: 34455391; PMCID: PMC8399064.
Copy Download .nbib Format: NLM
Showing 805 to 811 of 811 entries